Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU

Completed

Conditions: Acute Kidney Injury

Registration Number: NCT01294228

Lead Sponsor: Abbott RDx Cardiometabolic

Brief Summary: This is a multi-center, prospective, observational study of patients that are admitted to the intensive care unit (ICU). This study does not include any treatment or intervention and it is considered Nonsignificant Risk.

Detailed Description: The study will be conducted in two phases. Phase One is specimen acquisition and subject diagnosis adjudication. Phase Two is biomarker testing.

Phase One

Approximately 850 adults admitted to general ICUs will be enrolled within 12 hours of receipt of ICU admission orders. Study specific whole blood and urine specimens will be collected.

There is an Adjudication Committee for this study. This committee is comprised of qualified, board-certified nephrologists.

Phase Two

During Phase Two, the plasma specimens will be divided amongst three clinical sites representative of the intended end users of this assay, and tested under a separate testing protocol.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 1001

Inclusion Criteria

Subjects must be 21 years of age or older.
Subjects must be admitted to an Intensive Care Unit (medical or surgical) and must be enrolled into this study within 12 hours of receipt of ICU admission orders.
Subjects must be assessed as likely to be alive in the ICU for a minimum of 48 hours after enrollment.
The following plasma/serum creatinine values must be available:
Subjects that are admitted to the ICU following an elective surgery or procedure must have at least one pre-surgical/ pre-procedure creatinine value obtained in the 7 days prior to presentation to the ICU.
Subjects that are admitted to the ICU for any reason other than following an elective surgery or procedure must have at least one creatinine value obtained greater than 7 days and up to 6 months prior to presentation to the ICU.

Exclusion Criteria

Subjects either receiving or in imminent need of Renal Replacement Therapy.
Subjects with evidence of chronic kidney disease stages 4 and 5 as evidenced by a pre-enrollment estimated GFR of less than 30 mL/min/1.73M2 (according to the 4-variable MDRD22).
Subjects with any obstructive uropathy at the time of presentation to the ICU.
Subjects with any known urothelial, urological or kidney malignancies.
Subjects that have had any urologic procedure or surgery immediately prior to admission to the ICU.
Subjects that have had any renal transplant or nephrectomy.
Subjects that have had cardiovascular surgery involving cardiopulmonary bypass within the previous 7 days.
Subjects that have participated in an interventional clinical study within the previous 30 days including studies with any investigational and non-investigational drugs.
The inability to obtain written Informed Consent from the subject or an authorized representative.
Subjects that have been previously enrolled in this study during a prior admission to the ICU.

Exclusion Criteria

Not provided

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The Efficacy of the Triage Neutraphil-Gelatinase Associated Lipocalin (NGAL) Test as an Aid in the Diagnosis of Acute Kidney Injury (AKI) in an All-comers ICU Setting.	Prior to or within 72 hours.	The efficacy of the Triage Neutraphil-Gelatinase Associated Lipocalin (NGAL) Test as an aid in the diagnosis of acute kidney injury (AKI) in an all-comers ICU setting. Final AKI diagnoses were established by an adjudication committee.

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (28): University of Maryland Medical Center
🇺🇸
Baltimore, Maryland, United States
University of Pittsburgh Medical Center
🇺🇸
Pittsburgh, Pennsylvania, United States
Cleveland Clinic
🇺🇸
Cleveland, Ohio, United States
University Hospitals, Case Medical Center
🇺🇸
Cleveland, Ohio, United States
Cardiac and Vascular Research Center of Northern Michigan
🇺🇸
Petoskey, Michigan, United States
St. Francis Sleep Allergy and Lungs
🇺🇸
Clearwater, Florida, United States
LA County / USC Medical Center
🇺🇸
Los Angeles, California, United States
Kansas University Medical Center
🇺🇸
Kansas City, Kansas, United States
Northwestern University Feinberg School of Medicine
🇺🇸
Chicago, Illinois, United States
Cooper University Hospital
🇺🇸
Camden, New Jersey, United States
International Heart Institute of Montana
🇺🇸
Missoula, Montana, United States
Washington University School of Medicine
🇺🇸
St. Louis, Missouri, United States
New York Methodist Hospital
🇺🇸
Brooklyn, New York, United States
Mount Sinai Hospital
🇺🇸
New York, New York, United States
SUNY Stony Brook University Hospital
🇺🇸
Stony Brook, New York, United States
East Carolina University
🇺🇸
Greenville, North Carolina, United States
Hospital of the University of Pennsylvania
🇺🇸
Philadelphia, Pennsylvania, United States
Baylor College of Medicine
🇺🇸
Houston, Texas, United States
Vancouver Coastal Health
🇨🇦
Vancouver, British Columbia, Canada
Providence Regional Medical Center
🇺🇸
Everett, Washington, United States
Swedish Medical Center
🇺🇸
Seattle,, Washington, United States
St. Boniface Hospital
🇨🇦
Winnepeg, Manitoba, Canada
Capitol District Health Authority
🇨🇦
Halifax,, Nova Scotia, Canada
University of California, San Diego
🇺🇸
San Diego, California, United States
UC San Francisco General Hospital
🇺🇸
San Francisco, California, United States
Henry Ford Health System
🇺🇸
Detroit, Michigan, United States
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
Queen's Medical Center
🇺🇸
Honolulu, Hawaii, United States